Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version ~60% ACR 50 response maintained at week 52 2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met @RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm